10,500 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by IvyRock Asset Management HK Ltd

IvyRock Asset Management HK Ltd acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 10,500 shares of the biotechnology company’s stock, valued at approximately $362,000. Arrowhead Pharmaceuticals makes up approximately 0.2% of IvyRock Asset Management HK Ltd’s holdings, making the stock its 12th biggest position.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ARWR. Vanguard Group Inc. increased its position in shares of Arrowhead Pharmaceuticals by 3.3% in the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock valued at $553,077,000 after acquiring an additional 510,798 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Arrowhead Pharmaceuticals by 1.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock worth $47,067,000 after purchasing an additional 28,193 shares during the last quarter. Marshall Wace LLP increased its position in shares of Arrowhead Pharmaceuticals by 3,507.8% during the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after purchasing an additional 2,096,238 shares during the last quarter. Norges Bank bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $30,414,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after buying an additional 447,456 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Trading Down 3.2%

Shares of NASDAQ:ARWR opened at $61.62 on Thursday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $76.76. The business has a 50 day moving average of $66.28 and a 200-day moving average of $47.91. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. The stock has a market cap of $8.63 billion, a PE ratio of 40.27 and a beta of 1.21.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.38). The firm had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business’s revenue for the quarter was up 10461.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.39) earnings per share. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

ARWR has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 10th. Chardan Capital lifted their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. B. Riley Financial boosted their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Royal Bank Of Canada raised their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. Finally, The Goldman Sachs Group lifted their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.67.

Insider Activity at Arrowhead Pharmaceuticals

In related news, COO Patrick O’brien sold 49,493 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the transaction, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at approximately $29,971,443.88. This trade represents a 9.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Adeoye Y. Olukotun sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $67.66, for a total transaction of $676,600.00. Following the completion of the sale, the director owned 33,600 shares of the company’s stock, valued at $2,273,376. This trade represents a 22.94% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 510,836 shares of company stock valued at $33,603,060. 3.60% of the stock is currently owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.